Astellas Global

On April 1, 2005 Yamanouchi and Fujisawa merged to form Astellas.

Mission

Astellas Pharma Inc. develops and markets pharmaceuticals which provide the promise of a healthier life to people across the world. As a global pharmaceutical company Astellas is determined to be the ‘Leading Light for Life.’ This corporate message is directly reflected in Astellas’ business philosophy: “Contribute towards improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.”

Trusted therapies

Astellas is Japan's second largest pharmaceutical company and ranks fifteenth overall in the global market. Astellas has combined sales of around $7.3 billion with a portfolio including the BPH treatment Omnic/Flomax (called Harnal in Japan) and the immunosuppressant Prograf, widely used in transplantation. Recent global product launches include Vesicare for overactive bladder and Protopic for atopic dermatitis (eczema).

R&D

With a combined R&D budget of over $1.3 billion, Astellas has resources to develop innovative products in its existing franchise areas of Urology and Immunology (including transplantation and dermatology) as well as exploring new priority research areas - cardiovascular, diabetes, GI and CNS diseases. Read more about Astellas' R&D locations.

The Future

Through this merger Astellas will be able to realise its aspiration of becoming a global force in the provision of healthcare.